admitted with diarrhoea, or who developed diarrhoea following admission for an unrelated condition, were evaluated prospectively over 15 months. Stool was tested for Toxin A using standard enzyme immunoassay (EIA). DNA was extracted from toxin-positive stool and subsequently subjected to real-time PCR. Demonstration of an 18-base pair deletion of the tcd C gene, after amplification, indicated the presence of NAP1 strain. [4] CDAD was diagnosed in cases with diarrhoea that were confirmed Toxin A positive. Patients with diarrhoea and demonstrable pseudomembranous colitis at endoscopy or at histopathology were also diagnosed as having CDAD. Persons under 18 years of age, and adults who provided formed stool samples to the laboratory, were excluded from the study.
The Centres for Disease Control (CDC)-recommended definitions for diarrhoea were adopted. [5] Diarrhoea was considered as hospitalacquired if it had started more than 48 hours after admission, or if patients had resided in a long-term care facility, or if patients had been discharged from hospital or long-term care facility 14 days prior to presentation. CDAD was defined as diarrhoea that started before hospital admission or within 48 hours following admission.
The study was approved by the Ethics Committee of the University of Cape Town.
Statistical analysis
Statistical analysis was performed using Stata Statistical Software: Release 11 (StataCorp, College Station, USA). Continuous variables were expressed as medians and interquartile ranges (all variables in the final analysis had a non-Gaussian distribution). The Mann-Whitney test was used to assess continuous variables, while the chi-square or Fisher's exact test was used for categorical variables. Univariate analysis was performed initially for each variable. Variables differing between groups with a significance level of p<0.1 and other possible confounders identified a priori, were then entered into a series of multivariate logistic regression models. Age was treated as a categorical variable (<30 years, 30 -49 years, 50 -64 years, ≥65 years). Models were built sequentially, starting with the variable most strongly associated with the outcome. A p-value ≤0.05 was considered significant in the multivariate model. Some baseline variables that were significant on univariate analysis were omitted from the final models owing to collinearity. Different models were compared by using the likelihood ratio test, with significance determined at a p-value of 0.05.
Results
A total of 651 patients were enrolled. Eight were excluded owing to incomplete data, leaving 643 patients in the final analysis. Baseline characteristics are presented in Table 1 . Fifty-nine (9.2%) individuals were diagnosed with CDAD, of whom 34 (58%) were female. The diagnosis was made by toxin detection in 51 (86.4%) patients. An additional 6 (10.2%) had features of pseudomembranous colitis at endoscopy and 2 (3.4%) at histopathology.
Among the CDAD cases, 39 (66%) had had recent antibiotic exposure (within 28 days of diagnosis) and 27 (46%) had been hospitalised within the previous 3 months; both variables were significantly associated with C. difficile infection on univariate analysis. Sixty-four per cent of patients with CDAD had been exposed to penicillin-based antibiotics -26% to quinolones, 23% to carbapenems, 13% to cephalosporins and 3% to clindamycin. Although not statistically significant, there was a trend for increased use of proton pump inhibitors (PPIs) in subjects with CDAD compared with those without (49% v. 39%, p=0.089). No baseline laboratory marker was significantly associated with CDAD ( Table 2 ). On logistic regression analysis (Table 3) , only recent antibiotic exposure was identified as an independent predictor for CDAD (odds ratio (OR) 2.9; 95% CI 1.6 -5.1).
HA-CDAD was diagnosed in 40 subjects (67.8%), 90% of whom had had recent exposure to antibiotics, giving an annual incidence of HA-CDAD of 8.7 cases per 10 000 hospitalisations. Of the 19 (32.2%) patients with CA-CDAD, only 3 (16%) reported recent exposure to antibiotics, compared with 90% with HA-CDAD (p<0.0001). Fourteen (24%) patients with CDAD had concomitant IBD, 12 (86%) of whom acquired the disease in the community (p<0.0001 v. HA-CDAD). Table 4 compares the characteristics of HA-CDAD with CA-CDAD. Subjects with HA-CDAD had a significantly lower median baseline haemoglobin (8 g/dl v. 12 g/dl, p<0.0001) and serum albumin (24 g/l v. 41.5 g/l, p<0.0001) as well as significantly higher (Table  5) , which on regression analysis was significantly associated with C. difficile infection (OR 6.83; 95% CI 2.41 -19.3). However, no difference was observed in duration of hospital stay or the need for ICU care between subjects with and without C. difficile infection. There was no significant difference in mortality rates; the 30-day mortality rate for subjects with CDAD was 66.7%. Two (3.4%) cases of HA-CDAD owing to NAP1 were identified, both of which proved fatal.
Forty-four (74.6%) patients with CDAD were treated with metronidazole, 3 (5.2%) with oral vancomycin and 8 (13.4%) with a combination of oral vancomycin and metronidazole. Four (6.8%) patients received no antibiotics directed at C. difficile, 2 of whom underwent colectomy. Three (5.1%) patients had recurrent disease, all being successfully treated with antibiotics.
Discussion
Over the last decade, there has been concern about the rising incidence, disease severity and mortality associated with CDAD. The number of reported cases in the UK rose from 7 470 in 1994 to 43 682 in 2004. Stoke Mandeville Hospital reported 2 outbreaks between 2003 and 2005 that resulted in 38 deaths. [6] Similarly in Quebec, Canada, the overall incidence of CDAD quadrupled in 2003, with a reported 30-day mortality of 6.9% in one study. [7] This markedly increased incidence has been attributed to the NAP1 strain of C. difficile that carries a mutation in the tcd C gene, a negative regulator of toxin production, as a result of which the NAP1 strain produces more than 10 times the quantity of toxin than conventional strains. [3] NAP1 also produces an additional toxin, the so-called Binary toxin, which may act synergistically with Toxins A and B in causing disease. [8, 9] In southern Africa, data regarding C. difficile are scarce. Samie et al. undertook PCR detection of C. difficile in adults attending an outpatient department and in school-going children in the Vhembe District, South Africa. [10] They found a prevalence of 14% of C. difficile among study participants. However, the incidence of CDAD in SA hospitals remains undetermined. In 2008, Lekalakala et al. reported on an increase in CDAD at their tertiary hospital in Pretoria and highlighted the importance of preventive measures involving close co-ordination between the laboratory and infection control teams. [11] Whether this apparent increase was caused by the NAP1 strain was not evaluated.
Overall, the annual incidence of HA-CDAD was 0.87 cases per 1 000 hospitalisations, which is far lower than Western experience, where CDAD incidence rates of 7.4 cases per 1 000 admissions have been reported. [12] A possible explanation for this lower burden of disease may be the generally younger SA hospital patient population. The median age in our study was 41 years. However, when comparing patients 65 years and older with those 30 years and younger, an increased risk of developing CDAD was not observed (OR 0.7, 95% CI 0.3 -1.8). Another possible explanation may be the strict antimicrobial stewardship programme adopted at GSH, given that limiting the use of antibiotics has been shown to decrease the occurrence of CDAD. [13, 14] The possibility remains that all cases of C. difficile might not have been identified, and the incidence of CDAD underestimated. Stool EIA for Toxin A lacks sensitivity and may miss cases producing toxin B only. [4, 9] Another study limitation is that our hospital is a large, urban, tertiary-care teaching facility that may not be representative of other institutions.
Several risk factors render patients vulnerable to CDAD. The only independent variable in this study that was found to be strongly associated with CDAD, was recent exposure to antibiotics. [15] [16] [17] The hospital milieu serves as an important reservoir for resistant spores that may be passed on to individuals who then develop disease some time after exposure. Although univariate analysis suggested an increased risk of CDAD in subjects previously admitted to a healthcare facility within 90 days (p=0.014), significance was lost on multivariate analysis. SA is a high HIV-prevalent country, yet CDAD was not associated in this study with HIV infection. The relationship between CDAD and PPIs remains controversial, [18] but their use was shown not to significantly increase the risk for CDAD in this study.
While an elevated white cell count, hypo-albuminaemia, impaired renal function and raised inflammatory markers have been associated with severe CDAD, we did not find these parameters to be of significance. However, it bears noting that our control group also had serious illnesses with abnormal inflammatory and other markers. Similarly, the length of hospital stay, need for ICU admission, and mortality as outcome of disease did not reach significance. It is important to note that 1 in 5 patients who developed CDAD during the course of their illness eventually died. Subjects with CDAD had an almost seven-fold increase in colectomy.
Several reports have highlighted an increased incidence of CDAD in patients with IBD. [19] [20] [21] [22] [23] As in our study, it has been noted that IBD patients are particularly prone to CA-CDAD, even during remission and often without prior exposure to antibiotics. [24] In conclusion: This is the first study, to our knowledge, that prospectively documents the impact of CDAD in a southern African hospital. The burden of disease is significantly lower than in the West, perhaps because the NAP1 strain has fortunately not reached the levels reported in countries recently experiencing severe outbreaks.
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